Abstract:CC-90009 is a novel cereblon E3 ligase modulator (CELMoD) currently under investigation in a phase I clinical study in relapsed or refractory acute myeloid leukemia (R/R AML) (CC-90009-AML-001; NCT02848001). CC-90009 coopts the CUL4-DDB1-CRBN-RBX1 (CRL4CRBN) E3 ubiquitin ligase complex to target the translation termination factor G1 to S phase transition 1 (GSPT1) for ubiquitination and proteasomal degradation, resulting in rapid induction of apoptosis and growth inhibition in AML cell lines and primary patient blasts. To further elucidate the mechanism of action of CC-90009 in AML, we performed a genome-wide CRISPR/Cas9 screen to identify gene(s) whose knockout abrogate(s) the response to CC-90009 in a sensitive AML cell line. In addition to well-established key regulatory proteins required for the activity of all known cereblon modulators, which include components of the CRL4CRBN complex, E2 ubiquitin conjugating enzymes UBE2G1 and UBE2D3, and members of the neddylation and deneddylation machinery, interestingly, the screen identified the ILF2 and ILF3 heterodimeric complex as a novel regulator of cereblon expression. Knockout of ILF2/ILF3 decreased the production of full-length CRBN transcript via modulating alternative splicing of CRBN mRNA, leading to significant downregulation of cereblon expression and hence diminished response to CC-90009. The screen also revealed that mTOR signaling and the integrated stress response (ISR) specifically regulate the response to CC-90009 in contrast to other cereblon modulators. Since CC-90009 inhibits protein translation, it is reasonable to expect interactions with regulators of this pathway. Hyperactivation of the mTOR pathway by inactivation of TSC1 and TSC2 protected against the growth inhibitory effect of CC-90009 , at least in part by reducing CC-90009 induced binding of GSPT1 to cereblon and subsequent GSPT1 degradation. On the other hand, GSPT1 degradation promoted the activation of the GCN1/GCN2/ATF4 pathway and subsequent apoptosis in AML cells. Loss of GCN2 significantly attenuated the growth inhibitory effect of CC-90009, and this effect can be rescued with GCN2 wild-type but not enzymatically-dead mutants. Collectively, the antitumor activity of CC-90009, a first-in-class GSPT1 degrader, in AML cell lines is mediated by multiple layers of signaling networks and machinery, the elucidation of which reveals the underlying mechanism by which CC-90009 exerts its anti-AML activity and informs on the pathways for further study of CC-90009's clinical utility. Disclosures Lu: Celgene Corporation: Employment, Equity Ownership. Surka:Celgene: Employment, Equity Ownership. Lu:Celgene Corporation: Employment, Equity Ownership. Jang:Celgene: Employment, Equity Ownership. Wang:Celgene: Employment, Equity Ownership. Rolfe:Celgene: Employment, Equity Ownership.

Cereblon Promotes the Ubiquitination and Proteasomal Degradation of Interleukin Enhancer-Binding Factor 2

The interacting domains in cereblon differentially modulate the immunomodulatory drug-mediated ubiquitination and degradation of its binding partners.

Cereblon Suppresses the Lipopolysaccharide-Induced Inflammatory Response by Promoting the Ubiquitination and Degradation of C-Jun

UBE2G1 Governs the Destruction of Cereblon Neomorphic Substrates

CBLN2 Overexpression Inhibits Colorectal Cancer Progression and Improves Immunotherapy Responses

A Novel Cereblon Modulator Recruits GSPT1 to the CRL4 CRBN Ubiquitin Ligase

UBE2G1 governs the destruction of cereblon neomorphic substrates.

The Ubiquitination-Dependent and -Independent Functions of Cereblon in Cancer and Neurological Diseases

CRL4 Antagonizes SCFFbxo7-mediated Turnover of Cereblon and BK Channel to Regulate Learning and Memory

Elucidating the Mechanism of Action of CC-90009, a Novel Cereblon E3 Ligase Modulator, in AML Via Genome-Wide CRISPR Screen

Cereblon Attenuates DNA Damage-Induced Apoptosis by Regulating the Transcription-Independent Function of P53

Cereblon Modulators Target ZBTB16 and Its Oncogenic Fusion Partners for Degradation Via Distinct Structural Degrons.

Caspase-8 Inhibition Prevents the Cleavage and Degradation of E3 Ligase Substrate Receptor Cereblon and Potentiates Its Biological Function

Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes

Abstract SY37-02: Ligand-directed Degradation of GSPT1 by a Novel Cereblon Modulator Drives Potent Antitumor Effects

Cereblon Suppresses the Formation of Pathogenic Protein Aggregates in a P62-Dependent Manner.

A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.

CC-122, a Pleiotropic Pathway Modifier, Mimics an Interferon Response and Has Antitumor Activity in DLBCL

CC-90009, a Novel Cereblon E3 Ligase Modulator, Targets Acute Myeloid Leukemia Blasts and Leukemia Stem Cells.

Induction of CRBN(Cereblon) Mrna Expression by Baicalein

Cereblon, a Molecular Target of Lenalidomide (imids), Negatively Regulates T Cell Activation (IRM7P.715)